

---

Jacobs SS, Stork L, Bostrom BC, Hutchinson R, Holcenberg J, Reaman GH, Erdmann G, Franklin J, Neglia J, Steinberg S, Balis F, Adamson P. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). *Pediatr Blood Cancer*; 49(3):250-255, 2007.

1942; Acute Lymphoblastic Leukemia Disease Committee; Research Paper. COG # 8139

Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris M, Shuster J. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. *J Pediatr Hematol Oncol*; 29(9):627-632, 2007.

8602; Acute Lymphoblastic Leukemia Disease Committee; Research Paper. COG # 8488

Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz R, Wiseman GA, Harrison L, Kohl VK, Adamson P, Ayello J, van de Ven C, Perkins S, Cairo M. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20 positive non-Hodgkin's lymphoma: a Children's Oncology Group study. *Clin Cancer Res*; 13:5652s-5660s, 2007.

ADVL0013; Developmental Therapeutics Scientific Committee, Non-Hodgkin's Lymphoma Disease Committee; Research Paper. COG # 8595

Baker D, Schmidt ML, Cohn S, London W, Buxton A, Sandler A, Shimada H, Matthay KK. A Phase III trial of biologically-based therapy reduction for intermediate risk neuroblastoma. *Am Soc Clin Oncol*; ;, 2007.

A3961; Neuroblastoma Disease Committee; Abstract. COG # 8605

McGregor LM, Spunt SL, Furman WL, Stewart CF, Krailo M, Speights R, Houghton P, Ivy SP, Blaney S, Adamson P. A phase I study of oxaliplatin (OXA) and irinotecan (IRN) in pediatric patients with refractory solid tumors: a Children's Oncology Group study. *Am Soc Clin Oncol*; 25:9546, 2007.

ADVL0415; Developmental Therapeutics Scientific Committee; Abstract. COG # 8622

George RE, Lahti J, Ingle AM, Blaney S, Adamson P, Krailo M, Kidd VJ, Murgu A, Diller L. Decitabine (DAC) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in relapsed neuroblastoma (NBL): A Children's Oncology Group Study. *Am Soc Clin Oncol*; 25:9565, 2007.

Developmental Therapeutics Scientific Committee; Abstract. COG # 8623

Alonzo T, Nakas CT. Comparison of ROC umbrella volumes with an application to the assessment of lung cancer diagnostic markers. *Biometrical J*; 49:654-664, 2007.

Statistics Discipline Committee; Research Paper. COG # 8625

Raetz E, Cairo M, Borowitz M, Blaney S, Krailo M, Leil TA, Goldenberg DM, Wegener WA, Carroll WL, Adamson P. Chemoimmunotherapy reinduction with epratuzumab in children with ALL with marrow relapse: A Children's Oncology Group (COG) pilot study (ADVL04P2). *Am Soc Clin Oncol*; 25:9513, 2007.

ADVL04P2; Acute Lymphoblastic Leukemia Disease Committee, Developmental Therapeutics Scientific Committee; Abstract. COG # 8632

Perentesis J, Wagner LM, Ames MM, Reid JM, Stewart CF, Ingle AM, Blaney S, Adamson P. Phase I study of oral irinotecan, temozolomide, and vincristine for children with refractory solid tumors: a Children's Oncology Group study. *Am Soc Clin Oncol*; 25:9563, 2007.

ADVL0414; Developmental Therapeutics Scientific Committee; Abstract. COG # 8633

Fouladi M, Nicholson HS, Zhou T, Laningham FH, Helton K, Holmes E, Cohen KJ, Speights R, Wright J, Pollack I. Phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high grade glioma, medulloblastoma/PNET or brainstem glioma: A Children's Oncology Group Study. *Cancer*; 110(11):2535-2541, 2007.

ACNS0226; Central Nervous System Tumor Disease Committee; Research Paper. COG # 8676

---

Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro N, Fagin JA, Nikiforov YE. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. *J Clin Endocrinol Metab*; 88(11):5399-404, 2007.

Biopathology and Translational Research Scientific Committee; Research Paper. COG # 8984

Jacobs SS, Stork L, Bostrom BC, Hutchison R, Holcenberg J, Reaman GH, Erdmann G, Franklin J, Neglia J, Steinberg S, Balis F, Adamson PC. DUPLICATE - 8139 Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: A collaborative children's oncology group/national cancer institute pilot trial (CCG-1942).

*Pediatr Blood Cancer*; 49(3):250-255, 2007.

1942; Acute Lymphoblastic Leukemia Disease Committee; Research Paper. COG # 9011

Dreyer Z, Dinndorf P, Sather H, Steuber CP, Carroll WL, Hilden JM, Camitta BM. Shortened, intensified therapy in infant ALL: a Pediatric Oncology Group study. *Pediatr Blood Cancer*; 48:605, 2007.

P9407; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9025

Matloub YH, Angiolillo A, Bostrom BC, Stork L, Hunger S, Nachman J, Sather H, La MK, Carroll WL, Gaynon PS. Augmented Berlin-Frankfurt-Muenster (ABFM) regimen for children with standard-risk acute lymphoblastic leukemia (SR-ALL) and slow early response (SER). *J Clin Oncol*; 25:528s, 2007.

1991; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9065

Winick N, Martin PL, Devidas M, Shuster J, Borowitz M, Bowman P, Larsen EC, Pullen J, Hunger S, Carroll WL, Camitta BM. Delayed Intensification (DI) Enhances Event-Free Survival (EFS) Of Children with B-precursor acute lymphoblastic leukemia (ALL) who received intensification therapy with six courses of intravenous methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG). *Blood*; 110:583, 2007.

9904, 9905; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9253

Chang MN, Devidas M, Andersen JW. One- and two-stage designs for phase II window studies. *Stat Med*; :, 2007.

Statistics Discipline Committee; Research Paper. COG # 9314

Zhang L, Anglesio MS, Zhang F, Yang G, Sarao R, Cronin S, Hara H, Evdokimova V, Nghien M, Arya S, Wada T, Liu P, Sorensen PH, Penninger J. The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. *Nat Med*; 13:1060-1069, 2007.

Biopathology and Translational Research Scientific Committee; Research Paper. COG # 9318

Adamson P, Zhao H, Sievert A. A simulation study to define the number of patients necessary to meet primary pharmacokinetic (pk) aims of phase I oncology trials. *Am Soc Clin Oncol*; 25:2579, 2007.

Developmental Therapeutics Scientific Committee; Abstract. COG # 9320